Fallopian Tube Neoplasms: all 734 studies
Page 7 of 8. Open to participants first (128), then studies with results posted, then the rest; newest registration first within each.
- Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian CancerCompletedNCT00850772Phase 3
- Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by SurgeryCompletedNCT00842452Phase 1
- Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerStatus unknownNCT00838656Phase 2
- Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT00801320Not applicable
- AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CRCompletedNCT00770536Phase 1
- A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerSuspendedNCT00753480Phase 1
- Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTerminatedNCT00748527Phase 2
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus unknownNCT00719303Phase 3
- Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete RemissionWithdrawnNCT00693342Phase 3
- Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube CancerCompletedNCT00692900Phase 1
- PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal CancerCompletedNCT00672295Phase 1
- ChemoFx® PRO - A Post-Market Data Collection StudyTerminatedNCT00669422
- Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian OriginStatus unknownNCT00652119Phase 1
- A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.TerminatedNCT00637390Phase 1
- Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal CancerWithdrawnNCT00634894Phase 2
- Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum ChemotherapyCompletedNCT00602277Phase 1
- Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological CancerStatus unknownNCT00601406Not applicable
- Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00550784Phase 1
- Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase InhibitorCompletedNCT00543049Phase 2
- Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT00536523
- A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer PatientsCompletedNCT00526617Phase 1
- Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This QuestionnaireCompletedNCT00517621Phase 2
- Depression Treatment and Screening in Ovarian Cancer PatientsActive, not recruitingNCT00515372Phase 1
- Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube CancerStatus unknownNCT00499512
- Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerCompletedNCT00483782Phase 3
- Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal CancerCompletedNCT00479817Phase 2
- Dendritic Cell Vaccine for High Risk Ovarian Cancer PatientsCompletedNCT00478452Phase 1
- Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian CancerCompletedNCT00466986Phase 2
- Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal AdenocarcinomasCompletedNCT00443196Phase 2/3
- Pharmacogenomics of Paclitaxel in Ovarian CancerCompletedNCT00415207
- Pharmacogenomics of Paclitaxel in Ovarian CancerCompletedNCT00415181
- ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CarcinomaTerminatedNCT00407407Phase 1
- OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian CancerCompletedNCT00382811Phase 3
- Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or CarboplatinWithdrawnNCT00369954Phase 2
- Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube CancerCompletedNCT00357448Phase 1
- CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving TamoxifenStatus unknownNCT00305838Phase 2
- Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerTerminatedNCT00303888Phase 1
- Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic CancerCompletedNCT00295945
- Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube CancerTerminatedNCT00288275
- Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic CancerCompletedNCT00287885Phase 1
- Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerTerminatedNCT00287859Phase 1
- Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer PatientsCompletedNCT00268918Phase 1
- Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00263822Phase 3
- Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal CancerCompletedNCT00262990Phase 3
- Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic MassStatus unknownNCT00238342Not applicable
- Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian CancerCompletedNCT00230542Phase 2
- Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian CarcinomaCompletedNCT00226915Phase 3
- Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00217555Phase 2
- Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT00217529Phase 1/2
- A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.CompletedNCT00191607Phase 3
- Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early RelapseCompletedNCT00189566Phase 2
- Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late RelapseCompletedNCT00189553Phase 3
- Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or PeritoneumTerminatedNCT00189371Phase 3
- A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based TherapyCompletedNCT00189358Phase 2
- Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer PatientsCompletedNCT00189345Phase 2
- Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian CarcinomaCompletedNCT00157560Phase 2
- Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerCompletedNCT00138242Phase 2
- Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00126542Phase 2
- OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206CompletedNCT00112086Phase 2
- Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune ResponseCompletedNCT00103545Phase 1/2
- Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00098878Phase 3
- CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00096239Phase 2
- Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00091377Phase 1/2
- EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
- Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube CancersCompletedNCT00086567
- PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube CancerTerminatedNCT00085384Phase 1/2
- Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)CompletedNCT00085358Phase 1
- Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00079430Phase 1
- Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00075712Phase 2/3
- Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube CancerCompletedNCT00074867Phase 2
- UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00072267Phase 2
- Immunotoxin Therapy in Treating Patients With Advanced Solid TumorsCompletedNCT00066651Phase 1
- Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00066456Phase 1
- Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube CancerCompletedNCT00063401Phase 2
- Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal CancerCompletedNCT00061308Phase 2
- Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube CancerCompletedNCT00060359Phase 1
- PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube CancerCompletedNCT00059618Phase 1
- Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerCompletedNCT00058435Phase 1
- Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00055614Phase 1
- S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerTerminatedNCT00053833Phase 2
- Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube CancerCompletedNCT00052468Phase 3
- Gefitinib in Treating Patients With Cervical CancerCompletedNCT00049556Phase 2
- Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerStatus unknownNCT00045461Phase 2/3
- UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerCompletedNCT00045175Phase 1
- Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential TumorCompletedNCT00039585Phase 2
- EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal CancerCompletedNCT00035100Phase 2
- Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the PelvisCompletedNCT00033605Phase 3
- Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic CancerCompletedNCT00032162Phase 1/2
- Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerCompletedNCT00031954Phase 2
- Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00030446Phase 2
- Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00028912Phase 1
- Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00028743Phase 3
- TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00022347Phase 2
- Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00021034Phase 1
- Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal CancerCompletedNCT00019552Phase 2
- Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00019461Phase 2
- CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal CancerCompletedNCT00017017Phase 1/2
- ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00014690Phase 2
- Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or PeritoneumCompletedNCT00012090Phase 2
- Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial CancerCompletedNCT00010179Phase 2